Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $8.63 Consensus Price Target from Analysts
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the […]
